3.5 billion anti-tumor varieties! Qilu Pharmaceutical's first review

Recently, Qilu pharmaceutical received two specifications (0.5g and 0.15g) of capecitabine tablets approved and issued by the State Food and drug administration, approving the drug to pass the quality and efficacy consistency evaluation of generic drugs Capecitabine is the first in China to pass the consistency evaluation According to the data of minenet, in 2018, the sales volume of capecitabine tablet in the terminal of public medical institutions in China was 3.539 billion yuan, and capecitabine tablet of Qilu pharmaceutical was the first ever evaluated product Capecitabine is an anti-tumor drug, which is suitable for adjuvant chemotherapy of colon cancer It is mainly used in Dukes' C stage, after radical resection of primary tumor, and single drug adjuvant therapy of colon cancer patients who are suitable for fluoropyrimidine alone According to the data of minenet, in 2018, the sales of capecitabine tablets in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) were 3.539 billion yuan, up 10.96% year on year Sales of terminal capecitabine tablets of public medical institutions in China (unit: 10000 yuan) at present, there are 4 domestic enterprises with production approval documents of capecitabine tablets, including Roche, Hengrui, Zhengda Tianqing and Qilu Among them, Roche occupies 70% of the market share, Hengrui 13.9% and Qilu 10.52% In 2018, the consistency evaluation database of China's public medical institutions terminal capecitabine competition pattern on the intranet shows that Hengrui, Zhengda Tianqing and Qilu all submitted supplementary applications for the consistency evaluation of capecitabine Qilu took the lead in the evaluation, and Hengrui and Zhengda Tianqing are still under review Up to now, a total of 24 varieties of Qilu pharmaceutical have passed the consistency evaluation, 15 of which are the first in China.